Robert Fischer

CEO/CSO
Co-Founder

Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.

Simon Russell

CBO, Consultancy

Simon’s career began in R&D before gaining over 20 years’ experience in senior commercial and business roles in AstraZeneca, Novartis AG and biotech. Following his last role as Head of Strategic Marketing for Biologics at Novartis, he became CBO of Creabilis Ltd leading commercial, corporate and business development ultimately negotiating its sale to Sienna Biopharmaceuticals with its subsequent IPO on NASDAQ. He is a co-founder of a biotech emerging from the Basel incubator initiative. Dr Russell studied Chemistry at the University of Oxford and received a PhD from Southampton University.

Karen Uhlmann

Vice President Operations & IP
Co-Founder

Karen has more than 20 years’ experience in IP Asset Management, building and running organizations and being instrumental in raising funds, executing all different routes of commercialization. She holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, and has earned a business degree from the Chamber of Commerce Berlin..

Edita Bade

Head of Finance
& Controlling

Edita has gained more than 20 years of experience in various Finance, Controlling & Project Leader roles across a broad range of industries. Prior to joining OMEICOS, she supported the leadership team of an international Real Estate development company with the valuation and long-term value development projections of real estate opportunities, due diligence and acquisition/sales of these assets.

Henk Streefkerk

Clinical Development, Consultancy

Henk, MD PhD, joined OMEICOS as Consultant ‘Clinical Development’ in September 2020. Henk is a medical doctor with a PhD in neurosurgery from University of Utrecht. He held multiple medical roles in large companies (Organon, Novartis) and biotech (Actelion, PIQUR), in translational medicine, safety, and clinical development in cardiovascular, oncology, and orphan diseases. Most recently, he was CMO of an Oncology Biotech in Basel. Henk supports OMEICOS in the overall clinical development of OMT-28.

Markus Henrich

Medicinal Chemistry and CMC, Consultancy

Markus has more than 20 years of experience in various roles in the pharmaceutical industry, amongst them Executive Director Drug Discovery and Development at Merz Pharmaceuticals GmbH. In his current role as management consultant he constantly supports OMEICOS in the field of drug discovery and development. Areas of special expertise are innovation productivity and CMC.